A comprehensive view of Liver / Kidney / Bladder Health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Gilead completes acquisition of CymaBay Therapeutics for US$4.3B, enhancing its liver disease treatment portfolio with lead product candidate seladelpar for primary biliary cholangitis; CymaBay now a wholly owned subsidiary of Gilead
Published:
March 22, 2024
by Business Wire
|
Medtronic's renal denervation system gains Health Canada license to manage hypertension in patients with resistance to lifestyle changes and medication; the system uses radiofrequency ablation to calm nerves near the kidneys
Published:
March 20, 2024
by Contify Life Science News
|
Roche campaign highlights retinal diseases as major health concern, promotes gender equality in healthcare
Published:
March 15, 2024
by Industry Intelligence Inc.
|
GSK Group supports Kidney Health Australia's launch of updated kidney disease management handbook on World Kidney Day, reinforcing company's goal to expand public health education and healthcare services accessibility
Published:
March 14, 2024
by Industry Intelligence Inc.
|
Bayer AG focuses on innovation and tackling industry challenges, announces upcoming startups under G4A Acceleration Program, and is addressing chronic kidney disease and health issues related to diabetes.
Published:
March 12, 2024
by Industry Intelligence Inc.
|
Ask us about our Health Care Sector market view